Return to Clinical Trials Search Results

A Phase 3, Multicenter, Randomized, Open-Label Trial of Trastuzumab Deruxtecan versus Standard of Care (Carboplatin in Combination with Paclitaxel) as Adjuvant Treatment for HER2-expressing (IHC 3+/IHC 2+) Endometrial Cancer